Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase III LYM-3002 study

Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, Halyna Pylypenko, Noppadol Siritanaratkul, Juliana Pereira, Johannes Drach, Jiri Mayer, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Andrew Cakana, Helgi van de Velde, and Franco Cavalli

Disclosures: TR: Grants (Janssen); NS: Grants (Roche and GlaxoSmithKline); JD: Honoraria (Janssen); JM: Grants and personal fees (Janssen and Roche); RO: Grants (Janssen); LP: Employment (Janssen); BR: Employment (Janssen), equity ownership (Johnson & Johnson); HVdV: Employment (Millennium Pharmaceuticals, Inc. and Janssen), equity ownership (Johnson & Johnson); FC: Consultancy (Novartis and Takeda), research funding (Roche, Pfizer and Mundipharma); GV, HH, HP, JP: No disclosures

Contributions: Study design: GV, TR, JM, BR, AC, HVdV, FC Patient enrolment: TR, HH, HP, NS, JP, JD, JM, RO, AC Data collection: GV, TR, HH, JP, JD, JM, RO, AC Data analysis: JM, LP, BR, AC, HVdV Data interpretation: TR, JM, LP, BR, AC, HVdV, FC Wrote or contributed to the writing of the manuscript: All authors Provided approval of the final manuscript version for submission: All authors